You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Humanized Monoclonal Antibody to Treat Acinetobacter Infections

    SBC: BIOLOGICAL ANTI-INFECTIVE MEDICINES, LLC            Topic: NIAID

    DESCRIPTIONprovided by applicantNational surveillance data confirm thatof Abaumannii isolates from US intensive care units are extreme drug resistanceXDRfar higher than other pathogensAt leastandcases of XDR Abaumannii infections occur annually in the US and globallyin developed countriesrespectivelyThese infections result inanddeaths and excess healthcare costs of $million and $million in the US ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Rapid Immunodiagnosis of Drug-Resistant Bacterial Pathogens

    SBC: SILVER LAKE RESEARCH CORPORATION            Topic: NIAID

    PROJECT SUMMARY ABSTRACT This proposal describes Phase II of the development of a rapid immunoassay test kit for the determination oflactam antibiotic resistanceto be used as a point of care diagnostic test for urinary tract infectionsTodayantibiotics for UTI are prescribed empiricallywith no diagnostics available to clinicians to avoid treating resistant infections with the very drug to which the ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Preclinical Testing of a Novel Flow Diverting Stent for Treating Intracranial Aneurysms

    SBC: NeuroSigma, Inc.            Topic: 101

    DESCRIPTIONprovided by applicantThe purpose of this project is to develop an improvedminimally invasive treatment for intracranial aneurysmsIntracranial aneurysms are spherical outpouchings of blood vessels in the head that result from weakness in the vessel wallUnruptured aneurysms are present in approximatelyof the general populationand rupture can be devastating with a high morbidity and mortal ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  4. A user-friendly scalable microfluidic platform for enhanced neuron-cell culture

    SBC: Xona Microfluidics, Inc.            Topic: 101

    DESCRIPTIONprovided by applicantNeuron cell culture is widely used for studies in basic researchdrug discoveryand toxicity testingTraditional neuron cell culture approaches result in random growth of processes which prevent the study of their unique polarized morphologyOur goal is to provide robustuser friendlyand cost effective culture platforms to manipulate and access neurons and their subcellu ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Development of VLP vaccine for RSV

    SBC: SIGMOVIR BIOSYSTEMS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Respiratory syncytial virus RSV is a substantial threat to human health most severely affecting three large populations infants young children and the elderly Despite the significance of RSV disease in these different populations there are no vaccines available The goal of this Phase II STTR project is to continue preclinical testing of a novel RSV vac ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Real Time Oxygen Monitoring for Tissue Health Peripheral Artery Disease Application

    SBC: PROFUSA, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant Continuous biochemical monitoring has the power to change currently accepted standards of care shifting the emphasis from treating illness to maintaining health Point in time snapshots of a patientandapos s health can miss critical fluctuations or early warning signs that might warrant early interventions or changes in disease treatment and management PROFUS ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  7. The Allogeneic Heart Stem Cell Trial in Hypoplastic Left Heart Syndrome Patients

    SBC: CAPRICOR, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant One of the most complex forms of congenital heart disease hypoplastic left heart syndrome HLHS affects an average of in every newborns with a mortality rate of up to percent during the first year of life The overall goal f our research is to develop safe and effective ways to improve short term and long term survival rates in babies born with HL ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Urocortin Gene Transfer for CHF a Paracrine Approach Using Intravenous AAV

    SBC: Renova Therapeutics, Inc.            Topic: NHLBI

    DESCRIPTION provided by applicant Gene transfer for the treatment of cardiovascular diseases is bedeviled by inability to obtain safely and easily sufficient cardiac transgene expression Current methods of gene transfer for heart disease include intramuscular injection into heart muscle or intracoronary delivery approaches that are cumbersome to apply Consequently we have considered the u ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Nonlinear Computation Tool to Chart Trajectories of Bipolar Disorder

    SBC: Biomedical Development Corporation            Topic: 103

    DESCRIPTION provided by applicant Bipolar disorder BD is a complex chronic illness characterized by recurrent often dramatic mood changes Self management of BD is an important component of treatment but is likewise complex and can be fraught with difficulties including misunderstanding of the condition and a lack of self awareness Combined with the nationwide shortage of mental healthcare ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Modulation of the Innate Immune Response by Fisetin Derivatives for the Treatment of AD

    SBC: VIROGENICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant There are currently no drugs or other therapeutic interventions that can reverse or halt the progression of Alzheimerandapos s disease AD Age is by far the greatest risk factor for AD and it is known from studies in both mice and humans that neuroinflammation is increased with old age and to an even greater extent in AD Therefore a drug that could reduce ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government